Executive Summary
The PTAB initiated a sua sponte Director Review of an IPR involving Sinclair Pharma and others versus Hydrafacial, staying the proceeding after the ITC affirmed the claims’ validity and commercial success.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Samsung Electronics Co., Ltd. et al. vs Netlist, Inc. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Genius Sports Ltd.vsSportsCastr Inc.
Genius Sports Ltd. successfully convinced the PTAB to institute proceedings against SportsCastr Inc., finding a reasonable likelihood of prevailing on at least one claim. The Board found that claims 1-9 were obvious over combinations of prior art references, specifically demonstrating how known techniques could reduce data latency in live sports content delivery.
Samsung Electronics Co., Ltd. et al.vsNetlist, Inc.
Netlist seeks Director review to overturn the PTAB’s decision to institute an IPR against its 11,386,024 patent, arguing Samsung’s record is overly voluminous and its six grounds lack particularity. The petition urges denial of institution and referral to district court.
SAMSUNG ELECTRONICS CO., LTD. et al.vsOMNI MEDSCI, INC.
Samsung and co‑petitioners have filed a PGR seeking to invalidate claim 7 of Omni MedSci’s 12,193,790 patent, arguing obviousness over Lisogurski and Carlson and invoking collateral estoppel from earlier IPRs.
MICROSOFT CORPORATION et al.vsLiTL LLC
The PTAB denied institution of the IPR, finding that the Petitioner failed to demonstrate a reasonable likelihood of success in proving unpatentability. The claims related to graphical user interfaces (GUI) were challenged under 35 U.S.C. § 103(a).
WHOOP, Inc.vsOmni MedSci, Inc.
WHOOP has filed a Post‑Grant Review petition seeking cancellation of claim 7 of Omni MedSci’s ’790 wearable sensor patent. The petition alleges obviousness over Lisogurski combined with Carlson, Lamego, or Soller, and raises indefiniteness and lack of enablement under § 112. It also invokes collateral estoppel based on prior IPR findings.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.